A vaccine combining WT1 with PR1 was investigated by Rezvani et al. PR1 is an HLA-A*0201- restricted peptide derived from neutrophil elastase and proteinase-3 and is highly expressed in myeloid malignancies [129]. Here, TMEM37 is linked to myeloid neoplasm.